Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05816785 · ClinicalTrials.gov registry record · Early Phase 1
Pilot Study of Imatinib Cetuximab Combo for H & N Cancer
A Early Phase 1 study of Head and Neck Cancer and Squamous Cell Carcinoma of Head and Neck, sponsored by University of Wisconsin, Madison.
- Active
- Registry status
- Early Phase 1
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT05816785 is a Early Phase 1 study of Head and Neck Cancer and Squamous Cell Carcinoma of Head and Neck that is active but no longer recruiting, run by University of Wisconsin, Madison. The registered enrollment target is 15 participants, below the 261-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05816785, a Early Phase 1 study of Head and Neck Cancer and Squamous Cell Carcinoma of Head and Neck, is active but no longer recruiting, sponsored by University of Wisconsin, Madison.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to find if levels of a protein called AXL in tumor cells relate to how tumors respond to cetuximab (CTX) combined with imatinib in participants with head and neck cancer. This interventional study will occur in the time between diagnosis of your cancer and surgery to remove your tumor or radiation or chemoradiation treatment of your primary cancer. Participants will undergo a research blood draw and a research biopsy as part of the screening process, and will be in this research study for approximately 13 to 16 months.
Conditions Studied
Interventions
- DRUG Cetuximab
- DRUG Imatinib
Study Locations (1)
Wisconsin
- University of Wisconsin Carbone Cancer Center - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2023-04-18 |
| Est. Completion | 2026-04-30 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05816785
The ClinicalTrials.gov registry entry for NCT05816785 describes a study currently listed as active not recruiting, categorized as Early Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 261-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (94% lower). The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Head and Neck Cancer appearing as the primary indexed condition, and to 2 interventions - of which Cetuximab is the first listed.
NCT05816785 reports 1 study location spanning 1 distinct geographic area - top geographies include Wisconsin.
Frequently Asked Questions
What is clinical trial NCT05816785 about?
NCT05816785 is a clinical study titled "Pilot Study of Imatinib Cetuximab Combo for H & N Cancer". The goal of this clinical trial is to find if levels of a protein called AXL in tumor cells relate to how tumors respond to cetuximab (CTX) combined with imatinib in participants with head and neck cancer. This interventional study will occur in the time between diagnosis of your cancer and surgery ...
What is the current status of trial NCT05816785?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 15 participants. The study started on 2023-04-18. Estimated completion is 2026-04-30.
What conditions does trial NCT05816785 study?
This clinical trial studies the following conditions: Head and Neck Cancer, Squamous Cell Carcinoma of Head and Neck.
What interventions are being tested in trial NCT05816785?
The interventions under investigation include: Cetuximab (DRUG), Imatinib (DRUG).
Who is sponsoring clinical trial NCT05816785?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05816785 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Head and Neck Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Intraoral Hypothermia Device for Preserving Taste During Radiation
RECRUITING · Early Phase 1
-
Drug Screening Using Novel IMD in Salivary and Head and Neck Cancers
RECRUITING · Early Phase 1
-
Smoking Cessation Treatment for Head & Neck Cancer Patients
ACTIVE NOT RECRUITING · Early Phase 1
-
Pyrimethamine as an Inhibitor of NRF2 in HPV-unrelated Locally Advanced Head and Neck Squamous Cell Carcinoma
COMPLETED · Early Phase 1
-
Intratumoral Microdosing of TAK-981 in Head and Neck Cancer
COMPLETED · Early Phase 1
-
Curcumin Biomarker Trial in Head and Neck Cancer
COMPLETED · Early Phase 1
Explore more on PlainTrial
Head and Neck Cancer
All registered trials for this condition
Squamous Cell Carcinoma of Head and Neck
All registered trials for this condition
Wisconsin
All trials with a study site in Wisconsin
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.